Key Details
Price
$2.19Annual ROE
-43.00%Beta
1.55Events Calendar
Next earnings date:
Mar 21, 2025Recent quarterly earnings:
Nov 7, 2024Recent annual earnings:
Mar 21, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
Ntrust-2 open to enroll patients with systemic sclerosis, myositis and ANCA-associated vasculitis across three parallel cohorts
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference:
Raymond James upgraded Nkarta stock from outperform to a strong buy. The investment firm likes the biopharma's cash position and the opportunities for its lead candidate NKX019.
SOUTH SAN FRANCISCO, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the second quarter ended June 30, 2024.
SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced changes to its leadership team. Nadir Mahmood, Ph.D., will join Nkarta as President this month, sharing executive leadership responsibilities with Paul J. Hastings, who continues in his role as Chief Executive Officer. Additionally, Nkarta has broadened the role of David R. Shook, M.D., to Chief Medical Officer, Head of Research & Development. Drs. Mahmood and Shook will both report to Mr. Hastings.
For investors looking to maximize profits, marking the appropriate cheap stocks is essential. Here, the focus is on three exceptional businesses, each with solid arguments for being included in a sharp investment plan.
Patient screening underway in Ntrust-1, the first U.S.-based clinical trial of an engineered NK cell therapy for the treatment of lupus nephritis
Senior R&D leader brings extensive expertise in immunology, clinical development and translational science Senior R&D leader brings extensive expertise in immunology, clinical development and translational science
Nkarta Inc. is using natural killer cells engineered with CARs and membrane-bound IL-15 to target autoimmune diseases and oncology. The company's off-the-shelf availability and superior safety profile make it an attractive option for patients, providers, and payers. Nkarta is targeting large markets, such as lupus nephritis and non-Hodgkin lymphoma, with the potential to produce blockbuster therapies.
NKTX has experienced a more than 50% decline from its peak in March 2024. The company is working on developing NKX019, a CAR-NK cell therapy that shows promise in treating cancer and autoimmune disorders. Initial data on NKX019 in oncology has been released, with more data expected in the middle of the year. The company has also begun exploring the potential of NKX019 in treating autoimmune diseases in the first half of 2024.
FAQ
- What is the ticker symbol for Nkarta?
- Does Nkarta pay dividends?
- What sector is Nkarta in?
- What industry is Nkarta in?
- What country is Nkarta based in?
- When did Nkarta go public?
- Is Nkarta in the S&P 500?
- Is Nkarta in the NASDAQ 100?
- Is Nkarta in the Dow Jones?
- When was Nkarta's last earnings report?
- When does Nkarta report earnings?
- Should I buy Nkarta stock now?